BIOPHARMA
ByIs Biopharma’s $8.5 Billion AI Investment in 2025 Across Discovery, R&D, and Commercialization Shaping the 2026 Innovation Landscape?
Global – December 31, 2025 — Biopharmaceutical companies significantly increased investment in artificial intelligence (AI) in 2025, allocating…
Does Allarity Therapeutics’ Year-End Strategic Update Signal Renewed Momentum for Stenoparib in Hard-to-Treat Cancers?
Global – December 2025 — Allarity Therapeutics (NASDAQ: ALLR) has outlined key strategic and operational progress in its…
Do Wegovy Pricing Pathways in 2026 Signal a Turning Point for Obesity Drug Access and Market Expansion?
Global – December 2025 — A new pricing and access analysis for Wegovy (semaglutide) highlights how multiple reimbursement…
Does FDA Approval of Nereus Mark a Long-Awaited Breakthrough for Motion-Sickness Treatment—and a Turning Point for Vanda Pharmaceuticals?
Washington, D.C. – December 2025 — Vanda Pharmaceuticals achieved a major regulatory milestone after the U.S. Food and…
Can Gilead Sustain Growth Beyond HIV and Hepatitis in 2026?
Late January 2026 | Full-Year 2025 Earnings Preview | Antivirals, Oncology & Emerging Therapies Gilead Sciences is set…
Is AstraZeneca Building the Most Diversified Growth Engine in Global Pharma?
Late January–Early February 2026 | Full-Year 2025 Earnings Preview | Oncology, CVRM & Platform Innovation AstraZeneca is expected…
